Companies Exact Sciences Corp
Exact Sciences (EXAS): executive pay, fiscal 2024
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Exact Sciences Corp’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers55th pct.Of 22 peer CEOs
CEO pay, last three years
- $14,223,999FY2022
- $16,119,899FY2023
- $15,539,378FY2024
CEO total pay was $15,539,378 in fiscal 2024, down from $16,119,899 in fiscal 2023.
FY2024: salary $1,083,368 · bonus $0 · stock awards $13,496,138 · option awards $0
Executives and directors
Aaron Bloomer · CFOEverett Cunningham · EVPJacob Orville · EVPJeffrey Elliott · EVPBrian Baranick · EVPKevin Conroy · CEOSarah Condella · EVPD. Scott Coward · DirectorDaniel Levangie · Independent DirectorFreda Lewis-Hall · Former director (through FY2024)James Doyle · Lead Independent DirectorKatherine Zanotti · Independent DirectorKathleen Sebelius · Former director (through FY2024)Leslie Trigg · Independent DirectorMichael Barber · Independent DirectorPaul Clancy · Independent DirectorPierre Jacquet · Former director (through FY2024)Shacey Petrovic · Independent DirectorTimothy Scannell · Former director (through FY2024)
Frequently asked questions
Who was the highest-paid executive at Exact Sciences Corp in fiscal 2024?
As disclosed, Kevin Conroy (Chairman, President and Chief Executive Officer) was the highest-paid executive at Exact Sciences Corp in fiscal 2024, with total compensation of $15,539,378.
How does Exact Sciences Corp's chief executive pay compare to its disclosed peer group?
As disclosed, Kevin Conroy's total compensation ranked at the 55th percentile of Exact Sciences Corp's disclosed peer group.
What is Exact Sciences Corp's CEO-to-median employee pay ratio?
As disclosed, Exact Sciences Corp's CEO-to-median employee pay ratio was 109:1.
How did shareholders vote on Exact Sciences Corp's executive compensation?
As disclosed, 93.58% of shareholders supported Exact Sciences Corp's executive compensation in the latest say-on-pay vote.
How much does Exact Sciences Corp spend in total on board compensation for fiscal 2024?
As disclosed, Exact Sciences Corp reported total board compensation of $3,227,291 for fiscal 2024.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Kevin Conroy | $1,083,368 | $0 | $13,496,138 | $0 | $712,329 | $0 | $247,543 | $15,539,378 |
| Chairman, President and Chief Executive Officer | ||||||||
| Aaron Bloomer | 431,868 | 600,000 | 6,002,837 | 0 | 136,662 | 0 | 15,421 | 7,186,788 |
| Executive Vice President and Chief Financial Officer | ||||||||
| Jacob Orville | 618,000 | 0 | 3,581,298 | 0 | 202,812 | 0 | 31,082 | 4,433,192 |
| Executive Vice President and General Manager, Screening | ||||||||
| Brian Baranick | 600,400 | 0 | 3,581,298 | 0 | 196,980 | 0 | 20,990 | 4,399,668 |
| Executive Vice President and General Manager, Precision Oncology | ||||||||
| Everett Cunningham | 315,503 | 0 | 3,820,428 | 0 | 0 | 0 | 5,723 | 4,141,654 |
| Former Executive Vice President and Former Chief Commercial Officer | ||||||||
| Jeffrey Elliott | 392,176 | 0 | 273,173 | 0 | 0 | 0 | 2,556,092 | 3,221,441 |
| Former Executive Vice President and Former Chief Financial Officer | ||||||||
| Sarah Condella | 509,000 | 0 | 1,910,213 | 0 | 167,344 | 0 | 58,998 | 2,645,555 |
| Executive Vice President, Human Resources | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Kevin Conroy | $15,539,378 | $16,119,899 | $14,223,999 | ↓ −580,521 |
| Aaron Bloomer | 7,186,788 | — | — | — |
| Jacob Orville | 4,433,192 | 3,668,331 | 2,749,179 | ↑ +764,861 |
| Brian Baranick | 4,399,668 | 3,574,009 | — | ↑ +825,659 |
| Everett Cunningham | 4,141,654 | 4,546,966 | 5,176,570 | ↓ −405,312 |
| Jeffrey Elliott | 3,221,441 | 4,077,681 | 3,870,737 | ↓ −856,240 |
| Sarah Condella | 2,645,555 | 3,058,696 | 2,714,543 | ↓ −413,141 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The compensation program is designed to attract, motivate, and retain qualified executives by aligning their interests with long-term shareholder value creation. It emphasizes a pay-for-performance philosophy where a significant portion of compensation is variable and at-risk, tied to rigorous financial and operational performance targets and stock price performance.
| CEO STI target (% of salary) | 140% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2024
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Brian Baranick | PSU | 2024-02-26 | 1,237 | 19,792 | — | 44,533 | $1,249,469 |
| Sarah Condella | PSU | 2024-02-26 | 990 | 15,834 | — | 35,627 | 999,600 |
| Kevin Conroy | PSU | 2024-02-26 | 8,313 | 133,006 | — | 299,264 | 8,396,669 |
| Jacob Orville | PSU | 2024-02-26 | 1,237 | 19,792 | — | 44,533 | 1,249,469 |
| Jeffrey Elliott | RSU | 2024-02-26 | — | — | 4,750 | — | 273,173 |
| Aaron Bloomer | RSU | 2024-04-15 | — | — | 11,556 | — | 755,185 |
| Aaron Bloomer | RSU | 2024-04-15 | — | — | 51,619 | — | 3,373,302 |
| Sarah Condella | RSU | 2024-02-26 | — | — | 15,834 | — | 910,613 |
| Everett Cunningham | RSU | 2024-02-26 | — | — | 31,668 | — | 1,821,227 |
| Jacob Orville | RSU | 2024-02-26 | — | — | 19,793 | — | 1,138,295 |
| Aaron Bloomer | PSU | 2024-04-15 | 1,633 | 26,127 | — | 58,784 | 1,874,351 |
| Brian Baranick | RSU | 2024-02-26 | — | — | 19,793 | — | 1,138,295 |
| Brian Baranick | RSU | 2024-08-05 | — | — | 21,401 | — | 1,193,534 |
| Kevin Conroy | RSU | 2024-02-26 | — | — | 88,671 | — | 5,099,469 |
| Everett Cunningham | PSU | 2024-02-26 | 1,979 | 31,668 | — | 71,253 | 1,999,201 |
| Jacob Orville | RSU | 2024-08-05 | — | — | 21,401 | — | 1,193,534 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Brian Baranick | $2,331,829 | $1,249,469 | $0 | 34.9% |
| Sarah Condella | 910,613 | 999,600 | 0 | 52.3% |
| Kevin Conroy | 5,099,469 | 8,396,669 | 0 | 62.2% |
| Jacob Orville | 2,331,829 | 1,249,469 | 0 | 34.9% |
| Jeffrey Elliott | 273,173 | 0 | 0 | 0.0% |
| Aaron Bloomer | 4,128,487 | 1,874,351 | 0 | 31.2% |
| Everett Cunningham | 1,821,227 | 1,999,201 | 0 | 52.3% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2024
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Brian Baranick | RSU | 1,729 | — | $97,153 |
| Jacob Orville | RSU | 2,248 | — | 126,315 |
| Sarah Condella | RSU | 2,248 | — | 126,315 |
| Jacob Orville | RSU | 7,909 | — | 444,407 |
| Brian Baranick | RSU | 7,909 | — | 444,407 |
| Sarah Condella | RSU | 7,909 | — | 444,407 |
| Kevin Conroy | RSU | 10,374 | — | 582,915 |
| Sarah Condella | RSU | 11,340 | — | 637,195 |
| Aaron Bloomer | RSU | 11,556 | — | 649,332 |
| Jacob Orville | RSU | 14,175 | — | 796,493 |
| Brian Baranick | RSU | 14,175 | — | 796,493 |
| Sarah Condella | RSU | 15,834 | — | 889,712 |
| Jacob Orville | RSU | 19,793 | — | 1,112,169 |
| Brian Baranick | RSU | 19,793 | — | 1,112,169 |
| Jacob Orville | RSU | 21,401 | — | 1,202,522 |
| Brian Baranick | RSU | 21,401 | — | 1,202,522 |
| Kevin Conroy | RSU | 26,361 | — | 1,481,225 |
| Sarah Condella | PSU | 34,018 | — | 1,911,471 |
| Sarah Condella | PSU | 35,627 | — | 2,001,881 |
| Jacob Orville | PSU | 42,523 | — | 2,389,367 |
| Brian Baranick | PSU | 42,523 | — | 2,389,367 |
| Jacob Orville | PSU | 44,533 | — | 2,502,309 |
| Brian Baranick | PSU | 44,533 | — | 2,502,309 |
| Aaron Bloomer | RSU | 51,619 | — | 2,900,472 |
| Kevin Conroy | RSU | 54,429 | — | 3,058,366 |
| Aaron Bloomer | PSU | 58,784 | — | 3,303,073 |
| Kevin Conroy | RSU | 88,671 | — | 4,982,423 |
| Kevin Conroy | PSU | 244,931 | — | 13,762,673 |
| Kevin Conroy | PSU | 299,264 | — | 16,815,644 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Michael BarberIndependent · Audit and Finance · Innovation, Technology & Pipeline (Chair) · Newly elected | $102,500 | $571,183 | — | — | — | $673,683 |
| James DoyleIndependent · Lead Independent Director · Corporate Governance and Nominating · Human Capital | 127,500 | 253,892 | — | — | — | 381,392 |
| Paul ClancyIndependent · Audit and Finance (Chair) · Corporate Governance and Nominating | 102,500 | 253,892 | — | — | — | 356,392 |
| Daniel LevangieIndependent · Audit and Finance · Human Capital | 92,500 | 253,892 | — | — | — | 346,392 |
| Katherine ZanottiIndependent · Human Capital (Chair) | 90,000 | 253,892 | — | — | — | 343,892 |
| Kathleen SebeliusIndependent · Departed during FY | 87,500 | 253,892 | — | — | — | 341,392 |
| Shacey PetrovicIndependent · Corporate Governance and Nominating (Chair) | 85,000 | 253,892 | — | — | — | 338,892 |
| D. Scott CowardEmployee director · Innovation, Technology & Pipeline | 80,000 | 253,892 | — | — | — | 333,892 |
| Timothy ScannellIndependent · Not standing for re-election · Departed during FY | 0 | 111,364 | — | — | — | 111,364 |
| Freda Lewis-HallIndependent · Human Capital · Not standing for re-election · Departed during FY | 0 | 0 | — | — | — | 0 |
| Kimberly PopovitsIndependent · Human Capital · Innovation, Technology & Pipeline | 0 | 0 | — | — | — | 0 |
| Kevin ConroyEmployee director · Board Chair | — | — | — | — | — | 0 |
| Leslie TriggIndependent · Newly elected | 0 | 0 | — | — | — | 0 |
| Pierre JacquetIndependent · Not standing for re-election · Departed during FY | 0 | 0 | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $70,000 |
|---|---|
| Annual equity retainer | $300,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 15,000 |
| Stock ownership guideline | $5 |
Total cost of the board
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $767,500 |
| Equity awards (grant-date value) | $2,459,791 |
| All other compensation | $0 |
| Total cost of the board | $3,227,291 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Exact Sciences as a peer
Companies that benchmark against EXAS
21 companies name EXAS as a compensation peer
The list of companies that name EXAS as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2024
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
EW Edwards Lifesciences CorporationSGEN Seagen, Inc.HZNP Horizon Therapeutics Public Ltd CoPEN Penumbra, Inc.QDEL Quidel CorporationTXG 10x Genomics, Inc.A Agilent Technologies, Inc.BIO Bio-Rad Laboratories, Inc.TECH Bio-Techne CorporationILMN Illumina, Inc.GH Guardant Health, Inc.DXCM DexCom, Inc.HOLX Hologic, Inc.IDXX IDEXX Laboratories, Inc.PODD Insulet CorporationALNY Alnylam Pharmaceuticals, Inc.BMRN BioMarin Pharmaceutical Inc.INCY Incyte CorporationNTRA Natera, Inc.ALGN Align Technology, Inc.MASI Masimo CorporationRMD ResMed Inc.
Peer reciprocity
The companies Exact Sciences Corp names as compensation peers that name it back in their own disclosed peer groups.
Seagen, Inc. (SGEN)268Quidel Corporation (QDEL)26910x Genomics, Inc. (TXG)270Bio-Techne Corporation (TECH)271Guardant Health, Inc. (GH)272DexCom, Inc. (DXCM)273Insulet Corporation (PODD)274Alnylam Pharmaceuticals, Inc. (ALNY)275Natera, Inc. (NTRA)276
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Seagen, Inc. | 2022 | David Epstein | $190,385 | $14,815,386 | $42,381,246 | $0 | $57,460,546 |
| 2 | Incyte Corporation | 2025 | William Meury | 647,260 | 27,509,657 | 2,573,998 | 1,300,000 | 32,085,952 |
| 3 | BioMarin Pharmaceutical Inc. | 2025 | Alexander Hardy | 1,130,769 | 16,833,629 | 1,909,310 | 1,644,500 | 21,927,563 |
| 4 | Horizon Therapeutics Public Ltd Co | 2022 | Timothy Walbert | 1,292,727 | 16,601,305 | 0 | 0 | 20,103,869 |
| 5 | Masimo Corporation | 2025 | Catherine Szyman | 850,048 | 16,388,693 | 1,399,998 | 1,130,000 | 19,797,140 |
| 6 | Align Technology, Inc. | 2025 | Joseph Hogan | 1,400,000 | 16,556,872 | 0 | 1,220,100 | 19,193,988 |
| 7 | Insulet Corporation | 2025 | Ashley McEvoy | 729,808 | 12,958,850 | 2,999,913 | 2,031,562 | 18,858,968 |
| 8 | Edwards Lifesciences Corporation | 2025 | Bernard Zovighian | 1,192,500 | 7,167,024 | 6,499,109 | 2,406,537 | 17,454,255 |
| 9 | ResMed Inc. | 2026 | Michael Farrell | 1,272,895 | 9,749,468 | 3,249,907 | 1,738,857 | 16,201,649 |
| 10 | Hologic, Inc. | 2024 | Stephen MacMillan | 1,212,628 | 9,141,468 | 2,937,477 | 1,990,413 | 15,819,261 |
| 11 | Exact Sciences Corp | 2024 | Kevin Conroy | 1,083,368 | 13,496,138 | 0 | 712,329 | 15,539,378 |
| 12 | Natera, Inc. | 2025 | Steven Chapman | 853,710 | 12,979,558 | 0 | 1,114,151 | 14,957,319 |
| 13 | Alnylam Pharmaceuticals, Inc. | 2025 | Yvonne Greenstreet | 1,404,200 | 5,512,500 | 4,363,380 | 3,562,500 | 14,867,600 |
| 14 | Idexx Laboratories, Inc. | 2025 | Jonathan Mazelsky | 1,150,000 | 5,399,881 | 5,400,001 | 2,593,000 | 14,580,122 |
| 15 | Agilent Technologies, Inc. | 2025 | Padraig McDonnell | 1,141,345 | 8,169,850 | 2,017,759 | 1,436,809 | 12,827,236 |
| 16 | Quidel Corporation | 2025 | Brian Blaser | 1,000,000 | 8,965,822 | 0 | 1,274,500 | 11,255,782 |
| 17 | Illumina, Inc. | 2025 | Jacob Thaysen | 1,000,000 | 8,763,122 | 0 | 1,155,000 | 11,018,895 |
| 18 | Guardant Health, Inc. | 2025 | AmirAli Talasaz | 1 | 8,647,709 | 0 | 0 | 8,661,227 |
| 19 | Bio-Techne Corporation | 2025 | Kim Kelderman | 936,000 | 3,929,942 | 1,932,848 | 1,318,917 | 8,151,181 |
| 20 | Bio-Rad Laboratories, Inc. | 2025 | Norman Schwartz | 1,089,877 | 4,856,574 | 1,458,975 | 562,088 | 7,995,841 |
| 21 | DexCom, Inc. | 2025 | Jacob Leach | 768,962 | 5,936,062 | 0 | 1,164,780 | 7,985,960 |
| 22 | 10x Genomics, Inc. | 2025 | Serge Saxonov | 674,250 | 5,020,269 | 0 | 634,725 | 6,329,244 |
| 23 | Penumbra, Inc. | 2025 | Adam Elsesser | 850,000 | 0 | 0 | 0 | 851,621 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Exact Sciences Corp | 47% | PSU 60 · RSU 40 | No | Aon |
| 10x Genomics, Inc. | 93% | PSU 60 · RSU 40 | Yes — 3-year Relative TSR | Alpine Rewards LLC |
| Agilent Technologies, Inc. | not disclosed | PSU 60 · Option 20 · RSU 20 | No | Semler Brossy |
| Align Technology, Inc. | 58.1% | MSU 70 · RSU 30 | Yes — Relative Total Stockholder Return (TSR) vs. Nasdaq Composite Index | Compensia, Inc. |
| Alnylam Pharmaceuticals, Inc. | 200% | PSU 50 · RSU 25 · Option 25 | No | Pay Governance |
| Bio-Rad Laboratories, Inc. | not disclosed | not disclosed | not disclosed | Compensia, Inc. |
| Bio-Techne Corporation | 128.1% | PSU 50 · Options 25 · RSU 25 | No | Aon |
| BioMarin Pharmaceutical Inc. | 130% | PSU 66 · RSU 21 · Options 13 | Yes — Relative TSR | Aon Human Capital Solutions |
| DexCom, Inc. | not disclosed | not disclosed | Yes — Relative TSR Performance Metric | Aon Hewitt Consulting Company |
| Edwards Lifesciences Corporation | 127% | Options 50 · PSU 25 · RSU 25 | No | Semler Brossy Consulting Group |
| Guardant Health, Inc. | 140% | PSU 50 · RSU 50 · Option 35 | No | Aon |
| Hologic, Inc. | 109% | PSU 50 · RSU 25 · Option 25 | No | Pearl Meyer & Partners, LLC |
| Horizon Therapeutics Public Ltd Co | 100% | RSU 50 · PSU 50 | Yes — Relative TSR | Aon |
| Idexx Laboratories, Inc. | 140% | Options 50 · PSU 50 | No | Farient |
| Illumina, Inc. | not disclosed | not disclosed | Yes — 3-year rTSR performance against select companies in the Nasdaq Biotechnology Index | Aon |
| Incyte Corporation | 138.6% | Performance Shares 60 · RSU 40 | Yes — relative total shareholder return (TSR) | Aon |
| Insulet Corporation | 195.8% | PSU 60 · RSU 20 · Options 20 | No | Pearl Meyer & Partners, LLC |
| Masimo Corporation | not disclosed | not disclosed | not disclosed | FW Cook |
| Natera, Inc. | 131.1% | PSU 50 · RSU 50 | No | Aon |
| Penumbra, Inc. | not disclosed | not disclosed | No | Compensia |
| Quidel Corporation | not disclosed | PSU 60 · RSU 40 | Yes — Total Shareholder Return (TSR) | Compensia |
| ResMed Inc. | not disclosed | PSU 50 · RSU 25 · Options 25 | Yes — Relative TSR | FW Cook |
| Seagen, Inc. | 130% | RSU 60 · PSU 40 | Yes — Relative TSR | Aon |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-06-12 | 140,371,292 | 9,625,458 | 441,070 | 93.58% | Passed |
| 2024 | 2024-06-13 | 131,505,677 | 12,170,551 | 284,279 | 91.53% | Passed |
| 2023 | 2023-06-08 | 125,242,817 | 12,934,948 | 407,218 | 90.64% | Passed |
| 2022 | 2022-06-09 | 127,608,500 | 8,862,911 | 304,680 | 93.51% | Passed |
| 2021 | 2021-06-30 | 87,736,328 | 42,105,148 | 374,051 | 67.57% | Passed |
| 2020 | 2020-07-23 | 103,318,594 | 3,994,544 | 697,884 | 96.28% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2025 | 2025-06-12 | 93.58%a |
| 2024 | 2024-06-13 | 91.53%b |
| 2023 | 2023-06-08 | 90.64%c |
a. Approved under the standard stated in the filing — “Abstentions will therefor have no effect on Proposal 1.”.
b. Approved under the standard stated in the filing — “Broker non-votes and abstentions are not counted as votes cast on any proposal considered at the Annual Meeting and, therefore, will have no effect on Proposals 1 and 3.”.
c. Approved under the standard stated in the filing — “Broker non-votes and abstentions are not counted as votes cast on any proposal considered at the Annual Meeting and, therefore, will have no effect on Proposals 1, 3, 4, and 6.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 109 : 1 |
|---|---|
| CEO total compensation | $15,569,661 |
| Median employee compensation | $142,608 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| D. Scott Coward | Director | 2025-06-12 | A | 5,398 | $0 | $0 | Common | Form 4 ↗ |
| Daniel Levangie | Director | 2025-06-12 | A | 5,398 | 0 | 0 | Common | Form 4 ↗ |
| Shacey Petrovic | Director | 2025-06-12 | A | 5,398 | 0 | 0 | Common | Form 4 ↗ |
| Leslie Trigg | Director | 2025-06-12 | A | 7,670 | 0 | 0 | Common | Form 4 ↗ |
| Michael Barber | Director | 2025-06-12 | A | 7,197 | 0 | 0 | Common | Form 4 ↗ |
| Kimberly Popovits | Director | 2025-06-12 | A | 9,994 | 0 | 0 | Common | Form 4 ↗ |
| James Doyle | Director | 2025-06-12 | A | 5,398 | 0 | 0 | Common | Form 4 ↗ |
| Katherine Zanotti | Director | 2025-06-12 | A | 5,398 | 0 | 0 | Common | Form 4 ↗ |
| Paul Clancy | Director | 2025-06-12 | A | 5,398 | 0 | 0 | Common | Form 4 ↗ |
| Katherine Zanotti | Director | 2025-06-13 | D | 3,207 | 53 | 170,612 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-08-05 | D | 5,350 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-08-05 | D | 2,717 | 47 | 127,237 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-08-05 | A | 5,350 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-08-05 | A | 5,350 | 0 | 0 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-08-05 | D | 5,350 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-08-05 | D | 2,515 | 47 | 117,777 | Common | Form 4 ↗ |
| James Doyle | Director | 2025-08-13 | D | 1,485 | 42 | 62,400 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-10-09 | D | 1,500 | 60 | 90,000 | Common | Form 4 ↗ |
| James Doyle | Director | 2025-10-09 | D | 2,000 | 60 | 120,000 | Common | Form 4 ↗ |
| Katherine Zanotti | Director | 2025-10-24 | D | 12,000 | 65 | 780,000 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-11-04 | D | 2,858 | 70 | 200,289 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-11-04 | D | 1,500 | 70 | 105,120 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-11-19 | D | 1,000 | 70 | 70,000 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-11-19 | D | 5,000 | 75 | 375,000 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | A | 9,416 | 0 | 0 | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2025-12-23 | D | 38,715 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2025-12-23 | D | 10,803 | 102 | 1,099,961 | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2025-12-23 | A | 24,384 | 0 | 0 | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2025-12-23 | D | 17,151 | 102 | 1,746,315 | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2025-12-23 | A | 38,715 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 7,125 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 3,780 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2025-12-23 | — | 1,648 | — | — | 1 insider, 1 accrual row | ||
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 7,118 | 102 | 724,755 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 15,144 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 14,235 | 102 | 1,449,408 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 30,287 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 4,644 | 102 | 472,852 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 9,880 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 7,995 | 102 | 814,051 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 17,009 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 3,447 | 102 | 350,974 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 7,334 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 6,530 | 102 | 664,885 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 13,893 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 7,125 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 1,777 | 102 | 180,934 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 3,780 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 775 | 102 | 78,911 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 1,648 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2025-12-23 | A | 330,674 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2025-12-23 | D | 155,417 | 102 | 15,824,559 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2025-12-23 | D | 65,014 | 102 | 6,619,725 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2025-12-23 | D | 115,118 | 102 | 11,721,315 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2025-12-23 | A | 244,931 | 0 | 0 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 23,817 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 7,560 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 10,453 | 102 | 1,064,324 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | A | 20,584 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | A | 16,051 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 14,614 | 102 | 1,487,997 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 7,539 | 102 | 767,621 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | A | 9,450 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | A | 3,955 | 0 | 0 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 14,845 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 9,450 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 3,955 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 9,675 | 102 | 985,109 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | A | 20,584 | 0 | 0 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | A | 42,523 | 0 | 0 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 19,986 | 102 | 2,034,975 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 13,527 | 102 | 1,377,319 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 6,978 | 102 | 710,500 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | A | 14,845 | 0 | 0 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | A | 9,450 | 0 | 0 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | A | 3,955 | 0 | 0 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | A | 11,876 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | A | 42,523 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | A | 14,845 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 7,334 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 13,893 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 3,349 | 102 | 340,995 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 16,051 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 9,450 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | A | 34,018 | 0 | 0 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | A | 8,000 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 14,845 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 16,051 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 28,779 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 4,426 | 102 | 450,655 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | A | 16,051 | 0 | 0 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | A | 28,779 | 0 | 0 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 4,442 | 102 | 452,284 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 1,859 | 102 | 189,283 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 7,544 | 102 | 768,130 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 3,955 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 21,594 | 102 | 2,198,701 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 8,151 | 102 | 829,935 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | A | 28,779 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 4,799 | 102 | 488,634 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 2,009 | 102 | 204,556 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 28,779 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 11,876 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 3,955 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 3,760 | 102 | 382,843 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 11,194 | 102 | 1,139,773 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | A | 23,817 | 0 | 0 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 3,554 | 102 | 361,868 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | A | 7,560 | 0 | 0 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 1,859 | 102 | 189,283 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | A | 3,955 | 0 | 0 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 5,582 | 102 | 568,359 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 15,989 | 102 | 1,628,000 | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2025-12-23 | D | 24,384 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2025-12-23 | A | 138,326 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-24 | D | 14,938 | 102 | 1,517,551 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-24 | A | 29,416 | 0 | 0 | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2026-02-25 | A | 28,063 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-25 | A | 154,829 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-25 | A | 13,181 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-25 | D | 6,196 | 103 | 640,976 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2026-02-25 | A | 20,321 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-02-25 | A | 23,224 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2026-02-25 | A | 38,707 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2026-02-25 | A | 28,063 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-02-27 | D | 3,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-02-27 | D | 1,913 | 103 | 197,766 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | D | 27,786 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | D | 18,143 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | D | 13,060 | 103 | 1,348,445 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | D | 10,419 | 103 | 1,075,762 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | D | 8,528 | 103 | 880,516 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | A | 18,143 | 0 | 0 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-02-27 | A | 3,900 | 5 | 19,617 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | A | 27,786 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | D | 22,168 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | A | 22,168 | 0 | 0 | Common | Form 4 ↗ |
| Michael Barber | Director | 2026-03-23 | D | 5,398 | — | — | Common | Form 4 ↗ |
| Paul Clancy | Director | 2026-03-23 | D | 5,398 | — | — | Common | Form 4 ↗ |
| Paul Clancy | Director | 2026-03-23 | D | 20,640 | — | — | Common | Form 4 ↗ |
| James Doyle | Director | 2026-03-23 | D | 5,398 | — | — | Common | Form 4 ↗ |
| James Doyle | Director | 2026-03-23 | D | 52,564 | — | — | Common | Form 4 ↗ |
| Kimberly Popovits | Director | 2026-03-23 | D | 6,725 | — | — | Common | Form 4 ↗ |
| Katherine Zanotti | Director | 2026-03-23 | D | 5,398 | — | — | Common | Form 4 ↗ |
| Katherine Zanotti | Director | 2026-03-23 | D | 55,361 | — | — | Common | Form 4 ↗ |
| Shacey Petrovic | Director | 2026-03-23 | D | 5,398 | — | — | Common | Form 4 ↗ |
| D. Scott Coward | Director | 2026-03-23 | D | 4,175 | — | — | Derivative, Class A Common | Form 4 ↗ |
| D. Scott Coward | Director | 2026-03-23 | D | 5,398 | — | — | Common | Form 4 ↗ |
| D. Scott Coward | Director | 2026-03-23 | D | 52,164 | — | — | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2026-03-23 | D | 6,581 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2026-03-23 | D | 1,774 | — | — | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2026-03-23 | A | 53,323 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 154,829 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 83,360 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 18,143 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 100,916 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 34,110 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 235,388 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 86,750 | — | — | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 46,538 | — | — | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 29,061 | — | — | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-03-23 | D | 6,581 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-03-23 | D | 191,891 | — | — | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2026-03-23 | D | 4,395 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2026-03-23 | D | 417 | — | — | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2026-03-23 | D | 138,679 | — | — | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2026-03-23 | A | 89,911 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2026-03-23 | D | 20,321 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2026-03-23 | D | 2,861 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2026-03-23 | D | 793 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2026-03-23 | D | 1,762 | — | — | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2026-03-23 | D | 28,063 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2026-03-23 | D | 137,195 | — | — | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2026-03-23 | A | 33,321 | 0 | 0 | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2026-03-23 | D | 28,063 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Leslie Trigg | Director | 2026-03-23 | D | 3,244 | — | — | Common | Form 4 ↗ |
| Shacey Petrovic | Director | 2026-03-23 | D | 16,406 | — | — | Common | Form 4 ↗ |
| D. Scott Coward | Director | 2026-03-23 | D | 12,875 | — | — | Derivative, Class A Common | Form 4 ↗ |
| D. Scott Coward | Director | 2026-03-23 | D | 4,694 | — | — | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2026-03-23 | D | 38,707 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-03-23 | D | 23,224 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-03-23 | A | 60,389 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2026-03-23 | D | 68,195 | — | — | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2026-03-23 | D | 153,726 | — | — | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2026-03-23 | D | 795 | — | — | Common | Form 4 ↗ |
| Michael Barber | Director | 2026-03-23 | D | 7,422 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leslie Trigg | Director | 2026-03-23 | D | 13,925 | — | — | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-03-23 | D | 7,790 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-03-23 | D | 11,700 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-03-23 | D | 21,948 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-03-23 | D | 6,368 | — | — | Common | Form 4 ↗ |
| Kimberly Popovits | Director | 2026-03-23 | D | 9,656 | — | — | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 44,336 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 66,047 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 117,427 | — | — | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 1,397,738 | — | — | Common | Form 4 ↗ |
| D. Scott Coward | Director | 2026-03-23 | D | 10,786 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Barber | Director | 2026-03-23 | D | 7,738 | — | — | Common | Form 4 ↗ |
| Shacey Petrovic | Director | 2026-03-23 | D | 7,095 | — | — | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | A | 119,312 | 0 | 0 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 200 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| D. Scott Coward | Director | 2025-06-12 | A | 5,398 | $0 | $0 | Common | Form 4 ↗ |
| Daniel Levangie | Director | 2025-06-12 | A | 5,398 | 0 | 0 | Common | Form 4 ↗ |
| Shacey Petrovic | Director | 2025-06-12 | A | 5,398 | 0 | 0 | Common | Form 4 ↗ |
| Leslie Trigg | Director | 2025-06-12 | A | 7,670 | 0 | 0 | Common | Form 4 ↗ |
| Michael Barber | Director | 2025-06-12 | A | 7,197 | 0 | 0 | Common | Form 4 ↗ |
| Kimberly Popovits | Director | 2025-06-12 | A | 9,994 | 0 | 0 | Common | Form 4 ↗ |
| James Doyle | Director | 2025-06-12 | A | 5,398 | 0 | 0 | Common | Form 4 ↗ |
| Katherine Zanotti | Director | 2025-06-12 | A | 5,398 | 0 | 0 | Common | Form 4 ↗ |
| Paul Clancy | Director | 2025-06-12 | A | 5,398 | 0 | 0 | Common | Form 4 ↗ |
| Katherine Zanotti | Director | 2025-06-13 | D | 3,207 | 53 | 170,612 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-08-05 | D | 5,350 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-08-05 | D | 2,717 | 47 | 127,237 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-08-05 | A | 5,350 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-08-05 | A | 5,350 | 0 | 0 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-08-05 | D | 5,350 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-08-05 | D | 2,515 | 47 | 117,777 | Common | Form 4 ↗ |
| James Doyle | Director | 2025-08-13 | D | 1,485 | 42 | 62,400 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-10-09 | D | 1,500 | 60 | 90,000 | Common | Form 4 ↗ |
| James Doyle | Director | 2025-10-09 | D | 2,000 | 60 | 120,000 | Common | Form 4 ↗ |
| Katherine Zanotti | Director | 2025-10-24 | D | 12,000 | 65 | 780,000 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-11-04 | D | 2,858 | 70 | 200,289 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-11-04 | D | 1,500 | 70 | 105,120 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-11-19 | D | 1,000 | 70 | 70,000 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-11-19 | D | 5,000 | 75 | 375,000 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | A | 9,416 | 0 | 0 | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2025-12-23 | D | 38,715 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2025-12-23 | D | 10,803 | 102 | 1,099,961 | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2025-12-23 | A | 24,384 | 0 | 0 | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2025-12-23 | D | 17,151 | 102 | 1,746,315 | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2025-12-23 | A | 38,715 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 7,125 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 3,780 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 1,648 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 7,118 | 102 | 724,755 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 15,144 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 14,235 | 102 | 1,449,408 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 30,287 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 4,644 | 102 | 472,852 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 9,880 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 7,995 | 102 | 814,051 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 17,009 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 3,447 | 102 | 350,974 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 7,334 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 6,530 | 102 | 664,885 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 13,893 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 7,125 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 1,777 | 102 | 180,934 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 3,780 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 775 | 102 | 78,911 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 1,648 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2025-12-23 | A | 330,674 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2025-12-23 | D | 155,417 | 102 | 15,824,559 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2025-12-23 | D | 65,014 | 102 | 6,619,725 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2025-12-23 | D | 115,118 | 102 | 11,721,315 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2025-12-23 | A | 244,931 | 0 | 0 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 23,817 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 7,560 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 10,453 | 102 | 1,064,324 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | A | 20,584 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | A | 16,051 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 14,614 | 102 | 1,487,997 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 7,539 | 102 | 767,621 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | A | 9,450 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | A | 3,955 | 0 | 0 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 14,845 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 9,450 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 3,955 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 9,675 | 102 | 985,109 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | A | 20,584 | 0 | 0 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | A | 42,523 | 0 | 0 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 19,986 | 102 | 2,034,975 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 13,527 | 102 | 1,377,319 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 6,978 | 102 | 710,500 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | A | 14,845 | 0 | 0 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | A | 9,450 | 0 | 0 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | A | 3,955 | 0 | 0 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | A | 11,876 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | A | 42,523 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | A | 14,845 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 7,334 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 13,893 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 3,349 | 102 | 340,995 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 16,051 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 9,450 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | A | 34,018 | 0 | 0 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | A | 8,000 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 14,845 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 16,051 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 28,779 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 4,426 | 102 | 450,655 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | A | 16,051 | 0 | 0 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | A | 28,779 | 0 | 0 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 4,442 | 102 | 452,284 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 1,859 | 102 | 189,283 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 7,544 | 102 | 768,130 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 3,955 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 21,594 | 102 | 2,198,701 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 8,151 | 102 | 829,935 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | A | 28,779 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 4,799 | 102 | 488,634 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 2,009 | 102 | 204,556 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 28,779 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 11,876 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 3,955 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 3,760 | 102 | 382,843 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 11,194 | 102 | 1,139,773 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | A | 23,817 | 0 | 0 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 3,554 | 102 | 361,868 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | A | 7,560 | 0 | 0 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 1,859 | 102 | 189,283 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | A | 3,955 | 0 | 0 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 5,582 | 102 | 568,359 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 15,989 | 102 | 1,628,000 | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2025-12-23 | D | 24,384 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2025-12-23 | A | 138,326 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-24 | D | 14,938 | 102 | 1,517,551 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-24 | A | 29,416 | 0 | 0 | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2026-02-25 | A | 28,063 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-25 | A | 154,829 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-25 | A | 13,181 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-25 | D | 6,196 | 103 | 640,976 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2026-02-25 | A | 20,321 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-02-25 | A | 23,224 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2026-02-25 | A | 38,707 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2026-02-25 | A | 28,063 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-02-27 | D | 3,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-02-27 | D | 1,913 | 103 | 197,766 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | D | 27,786 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | D | 18,143 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | D | 13,060 | 103 | 1,348,445 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | D | 10,419 | 103 | 1,075,762 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | D | 8,528 | 103 | 880,516 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | A | 18,143 | 0 | 0 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-02-27 | A | 3,900 | 5 | 19,617 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | A | 27,786 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | D | 22,168 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | A | 22,168 | 0 | 0 | Common | Form 4 ↗ |
| Michael Barber | Director | 2026-03-23 | D | 5,398 | — | — | Common | Form 4 ↗ |
| Paul Clancy | Director | 2026-03-23 | D | 5,398 | — | — | Common | Form 4 ↗ |
| Paul Clancy | Director | 2026-03-23 | D | 20,640 | — | — | Common | Form 4 ↗ |
| James Doyle | Director | 2026-03-23 | D | 5,398 | — | — | Common | Form 4 ↗ |
| James Doyle | Director | 2026-03-23 | D | 52,564 | — | — | Common | Form 4 ↗ |
| Kimberly Popovits | Director | 2026-03-23 | D | 6,725 | — | — | Common | Form 4 ↗ |
| Katherine Zanotti | Director | 2026-03-23 | D | 5,398 | — | — | Common | Form 4 ↗ |
| Katherine Zanotti | Director | 2026-03-23 | D | 55,361 | — | — | Common | Form 4 ↗ |
| Shacey Petrovic | Director | 2026-03-23 | D | 5,398 | — | — | Common | Form 4 ↗ |
| D. Scott Coward | Director | 2026-03-23 | D | 4,175 | — | — | Derivative, Class A Common | Form 4 ↗ |
| D. Scott Coward | Director | 2026-03-23 | D | 5,398 | — | — | Common | Form 4 ↗ |
| D. Scott Coward | Director | 2026-03-23 | D | 52,164 | — | — | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2026-03-23 | D | 6,581 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2026-03-23 | D | 1,774 | — | — | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2026-03-23 | A | 53,323 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 154,829 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 83,360 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 18,143 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 100,916 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 34,110 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 235,388 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 86,750 | — | — | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 46,538 | — | — | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 29,061 | — | — | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-03-23 | D | 6,581 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-03-23 | D | 191,891 | — | — | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2026-03-23 | D | 4,395 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2026-03-23 | D | 417 | — | — | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2026-03-23 | D | 138,679 | — | — | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2026-03-23 | A | 89,911 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2026-03-23 | D | 20,321 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2026-03-23 | D | 2,861 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2026-03-23 | D | 793 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2026-03-23 | D | 1,762 | — | — | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2026-03-23 | D | 28,063 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2026-03-23 | D | 137,195 | — | — | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2026-03-23 | A | 33,321 | 0 | 0 | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2026-03-23 | D | 28,063 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Leslie Trigg | Director | 2026-03-23 | D | 3,244 | — | — | Common | Form 4 ↗ |
| Shacey Petrovic | Director | 2026-03-23 | D | 16,406 | — | — | Common | Form 4 ↗ |
| D. Scott Coward | Director | 2026-03-23 | D | 12,875 | — | — | Derivative, Class A Common | Form 4 ↗ |
| D. Scott Coward | Director | 2026-03-23 | D | 4,694 | — | — | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2026-03-23 | D | 38,707 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-03-23 | D | 23,224 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-03-23 | A | 60,389 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2026-03-23 | D | 68,195 | — | — | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2026-03-23 | D | 153,726 | — | — | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2026-03-23 | D | 795 | — | — | Common | Form 4 ↗ |
| Michael Barber | Director | 2026-03-23 | D | 7,422 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leslie Trigg | Director | 2026-03-23 | D | 13,925 | — | — | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-03-23 | D | 7,790 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-03-23 | D | 11,700 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-03-23 | D | 21,948 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-03-23 | D | 6,368 | — | — | Common | Form 4 ↗ |
| Kimberly Popovits | Director | 2026-03-23 | D | 9,656 | — | — | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 44,336 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 66,047 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 117,427 | — | — | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 1,397,738 | — | — | Common | Form 4 ↗ |
| D. Scott Coward | Director | 2026-03-23 | D | 10,786 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Barber | Director | 2026-03-23 | D | 7,738 | — | — | Common | Form 4 ↗ |
| Shacey Petrovic | Director | 2026-03-23 | D | 7,095 | — | — | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | A | 119,312 | 0 | 0 | Common | Form 4 ↗ |
Sources (276 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Kevin Conroy. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · page 74. As printed: 15,539,378. View filing ↗
- Section 01, Aaron Bloomer. DEF 14A, filed 2025-04-29. Section “Executive Compensation”. As printed: 7,186,788. View filing ↗
- Section 01, Jacob Orville. DEF 14A, filed 2025-04-29. Section “Executive Compensation”. As printed: 4,433,192. View filing ↗
- Section 01, Brian Baranick. DEF 14A, filed 2025-04-29. Section “Executive Compensation”. As printed: 4,399,668. View filing ↗
- Section 01, Everett Cunningham. DEF 14A, filed 2025-04-29. Section “Executive Compensation”. As printed: 4,141,654. View filing ↗
- Section 01, Jeffrey Elliott. DEF 14A, filed 2025-04-29. Section “Executive Compensation”. As printed: 3,221,441. View filing ↗
- Section 01, Sarah Condella. DEF 14A, filed 2025-04-29. Section “Executive Compensation”. As printed: 2,645,555. View filing ↗
- Section 03, Brian Baranick PSU. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Sarah Condella PSU. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Kevin Conroy PSU. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Jacob Orville PSU. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Jeffrey Elliott RSU. DEF 14A, filed 2025-04-29. Section “Grants of Plan-Based Awards in 2024” · grants of plan-based awards table. View filing ↗
- Section 03, Aaron Bloomer RSU. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Aaron Bloomer RSU. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Sarah Condella RSU. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Everett Cunningham RSU. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Jacob Orville RSU. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Aaron Bloomer PSU. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Brian Baranick RSU. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Brian Baranick RSU. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Kevin Conroy RSU. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Everett Cunningham PSU. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Jacob Orville RSU. DEF 14A, filed 2025-04-29. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2025-04-29. Section “CEO Pay Ratio”. As printed: 109 : 1. View filing ↗
- Section 08, Michael Barber. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 673,683. View filing ↗
- Section 08, James Doyle. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 381,392. View filing ↗
- Section 08, Paul Clancy. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 356,392. View filing ↗
- Section 08, Daniel Levangie. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 346,392. View filing ↗
- Section 08, Katherine Zanotti. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 343,892. View filing ↗
- Section 08, Kathleen Sebelius. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 341,392. View filing ↗
- Section 08, Shacey Petrovic. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 338,892. View filing ↗
- Section 08, D. Scott Coward. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 333,892. View filing ↗
- Section 08, Timothy Scannell. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 111,364. View filing ↗
- Section 08, Freda Lewis-Hall. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Kimberly Popovits. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Kevin Conroy. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Leslie Trigg. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Pierre Jacquet. DEF 14A, filed 2025-04-29. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, D. Scott Coward 2025-06-12. Form 4, filed 2025-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Levangie 2025-06-12. Form 4, filed 2025-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shacey Petrovic 2025-06-12. Form 4, filed 2025-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leslie Trigg 2025-06-12. Form 4, filed 2025-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Barber 2025-06-12. Form 4, filed 2025-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kimberly Popovits 2025-06-12. Form 4, filed 2025-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Doyle 2025-06-12. Form 4, filed 2025-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katherine Zanotti 2025-06-12. Form 4, filed 2025-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul Clancy 2025-06-12. Form 4, filed 2025-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katherine Zanotti 2025-06-13. Form 4, filed 2025-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Baranick 2025-08-05. Form 4, filed 2025-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Baranick 2025-08-05. Form 4, filed 2025-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacob Orville 2025-08-05. Form 4, filed 2025-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Baranick 2025-08-05. Form 4, filed 2025-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacob Orville 2025-08-05. Form 4, filed 2025-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacob Orville 2025-08-05. Form 4, filed 2025-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Doyle 2025-08-13. Form 4, filed 2025-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Herriott 2025-10-09. Form 4, filed 2025-10-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Doyle 2025-10-09. Form 4, filed 2025-10-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katherine Zanotti 2025-10-24. Form 4, filed 2025-10-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Baranick 2025-11-04. Form 4, filed 2025-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Herriott 2025-11-04. Form 4, filed 2025-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Herriott 2025-11-19. Form 4, filed 2025-11-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacob Orville 2025-11-19. Form 4, filed 2025-11-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacob Orville 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aaron Bloomer 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aaron Bloomer 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aaron Bloomer 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aaron Bloomer 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aaron Bloomer 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Herriott 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Herriott 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Herriott 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Herriott 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Herriott 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Herriott 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Herriott 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Herriott 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Herriott 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Herriott 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Herriott 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Herriott 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Herriott 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Herriott 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Herriott 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Herriott 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Herriott 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Herriott 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Herriott 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Herriott 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Conroy 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Conroy 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Conroy 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Conroy 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Conroy 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Condella 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Condella 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Baranick 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Baranick 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Baranick 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Baranick 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Baranick 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Baranick 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Baranick 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacob Orville 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacob Orville 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacob Orville 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacob Orville 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacob Orville 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacob Orville 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacob Orville 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacob Orville 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacob Orville 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacob Orville 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacob Orville 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacob Orville 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Condella 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Baranick 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Baranick 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Herriott 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Herriott 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Herriott 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Baranick 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Baranick 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Condella 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Condella 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Baranick 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacob Orville 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacob Orville 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacob Orville 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacob Orville 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacob Orville 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacob Orville 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacob Orville 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacob Orville 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Baranick 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Baranick 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Baranick 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Baranick 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Baranick 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Baranick 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Baranick 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Condella 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Condella 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Condella 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Condella 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Condella 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Condella 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Condella 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Condella 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Condella 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Condella 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Condella 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aaron Bloomer 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Conroy 2025-12-23. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Baranick 2025-12-24. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Baranick 2025-12-24. Form 4, filed 2025-12-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aaron Bloomer 2026-02-25. Form 4, filed 2026-02-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Conroy 2026-02-25. Form 4, filed 2026-02-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Conroy 2026-02-25. Form 4, filed 2026-02-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Conroy 2026-02-25. Form 4, filed 2026-02-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Herriott 2026-02-25. Form 4, filed 2026-02-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Condella 2026-02-25. Form 4, filed 2026-02-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacob Orville 2026-02-25. Form 4, filed 2026-02-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Baranick 2026-02-25. Form 4, filed 2026-02-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Condella 2026-02-27. Form 4, filed 2026-03-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Condella 2026-02-27. Form 4, filed 2026-03-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Conroy 2026-02-27. Form 4, filed 2026-03-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Conroy 2026-02-27. Form 4, filed 2026-03-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Conroy 2026-02-27. Form 4, filed 2026-03-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Conroy 2026-02-27. Form 4, filed 2026-03-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Conroy 2026-02-27. Form 4, filed 2026-03-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Conroy 2026-02-27. Form 4, filed 2026-03-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Condella 2026-02-27. Form 4, filed 2026-03-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Conroy 2026-02-27. Form 4, filed 2026-03-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Conroy 2026-02-27. Form 4, filed 2026-03-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Conroy 2026-02-27. Form 4, filed 2026-03-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Barber 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul Clancy 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul Clancy 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Doyle 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Doyle 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kimberly Popovits 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katherine Zanotti 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Katherine Zanotti 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shacey Petrovic 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, D. Scott Coward 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, D. Scott Coward 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, D. Scott Coward 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacob Orville 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacob Orville 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacob Orville 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Conroy 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Conroy 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Conroy 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Conroy 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Conroy 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Conroy 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Conroy 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Conroy 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Conroy 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Condella 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Condella 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aaron Bloomer 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aaron Bloomer 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aaron Bloomer 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aaron Bloomer 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Herriott 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Herriott 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Herriott 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Herriott 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Baranick 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Baranick 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Baranick 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aaron Bloomer 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leslie Trigg 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shacey Petrovic 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, D. Scott Coward 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, D. Scott Coward 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacob Orville 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Condella 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Condella 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Herriott 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jacob Orville 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brian Baranick 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Barber 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Leslie Trigg 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Condella 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Condella 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Condella 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Condella 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kimberly Popovits 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Conroy 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Conroy 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Conroy 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Conroy 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, D. Scott Coward 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Barber 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shacey Petrovic 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kevin Conroy 2026-03-23. Form 4, filed 2026-03-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-16. Item 5.07 · say-on-pay result. As reported: 93.58% (votes for as printed: 140,371,292). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-17. Item 5.07 · say-on-pay result. As reported: 91.53% (votes for as printed: 131,505,677). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-12. Item 5.07 · say-on-pay result. As reported: 90.64% (votes for as printed: 125,242,817). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 767,500 + equity 2,459,791 + all other 0 = 3,227,291, summed across the director compensation table rows.
- Seagen, Inc., Section 10b CEO total. DEF 14A, filed 2023-04-18. CEO total compensation as printed in Seagen, Inc.'s own proxy. As printed: 57,460,546. View filing ↗
- Incyte Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Incyte Corporation's own proxy. As printed: 32,085,952. View filing ↗
- BioMarin Pharmaceutical Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in BioMarin Pharmaceutical Inc.'s own proxy. As printed: 21,927,563. View filing ↗
- Horizon Therapeutics Public Ltd Co, Section 10b CEO total. DEF 14A, filed 2023-06-30. CEO total compensation as printed in Horizon Therapeutics Public Ltd Co's own proxy. As printed: 20,103,869. View filing ↗
- Masimo Corporation, Section 10b CEO total. 10-K/A, filed 2026-05-01. CEO total compensation as printed in Masimo Corporation's own proxy. As printed: 19,797,140. View filing ↗
- Align Technology, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Align Technology, Inc.'s own proxy. As printed: 19,193,988. View filing ↗
- Insulet Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Insulet Corporation's own proxy. As printed: 18,858,968. View filing ↗
- Edwards Lifesciences Corporation, Section 10b CEO total. DEF 14A, filed 2026-03-26. CEO total compensation as printed in Edwards Lifesciences Corporation's own proxy. As printed: 17,454,255. View filing ↗
- ResMed Inc., Section 10b CEO total. DEF 14A, filed 2026-10-01. CEO total compensation as printed in ResMed Inc.'s own proxy. As printed: 16,201,649. View filing ↗
- Hologic, Inc., Section 10b CEO total. DEF 14A, filed 2025-01-16. CEO total compensation as printed in Hologic, Inc.'s own proxy. As printed: 15,819,261. View filing ↗
- Exact Sciences Corp (subject), Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Exact Sciences Corp's own proxy. As printed: 15,539,378. View filing ↗
- Natera, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Natera, Inc.'s own proxy. As printed: 14,957,319. View filing ↗
- Alnylam Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Alnylam Pharmaceuticals, Inc.'s own proxy. As printed: 14,867,600. View filing ↗
- Idexx Laboratories, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Idexx Laboratories, Inc.'s own proxy. As printed: 14,580,122. View filing ↗
- Agilent Technologies, Inc., Section 10b CEO total. DEF 14A, filed 2026-02-06. CEO total compensation as printed in Agilent Technologies, Inc.'s own proxy. As printed: 12,827,236. View filing ↗
- Quidel Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Quidel Corporation's own proxy. As printed: 11,255,782. View filing ↗
- Illumina, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Illumina, Inc.'s own proxy. As printed: 11,018,895. View filing ↗
- Guardant Health, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Guardant Health, Inc.'s own proxy. As printed: 8,661,227. View filing ↗
- Bio-Techne Corporation, Section 10b CEO total. DEF 14A, filed 2025-09-19. CEO total compensation as printed in Bio-Techne Corporation's own proxy. As printed: 8,151,181. View filing ↗
- Bio-Rad Laboratories, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-25. CEO total compensation as printed in Bio-Rad Laboratories, Inc.'s own proxy. As printed: 7,995,841. View filing ↗
- DexCom, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in DexCom, Inc.'s own proxy. As printed: 7,985,960. View filing ↗
- 10x Genomics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in 10x Genomics, Inc.'s own proxy. As printed: 6,329,244. View filing ↗
- Penumbra, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Penumbra, Inc.'s own proxy. As printed: 851,621. View filing ↗
- Section 10a, Seagen, Inc. reciprocity. DEF 14A. Seagen, Inc. names Exact Sciences Corp in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Quidel Corporation reciprocity. DEF 14A. Quidel Corporation names Exact Sciences Corp in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, 10x Genomics, Inc. reciprocity. DEF 14A. 10x Genomics, Inc. names Exact Sciences Corp in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Bio-Techne Corporation reciprocity. DEF 14A. Bio-Techne Corporation names Exact Sciences Corp in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Guardant Health, Inc. reciprocity. DEF 14A. Guardant Health, Inc. names Exact Sciences Corp in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, DexCom, Inc. reciprocity. DEF 14A. DexCom, Inc. names Exact Sciences Corp in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Insulet Corporation reciprocity. DEF 14A. Insulet Corporation names Exact Sciences Corp in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Alnylam Pharmaceuticals, Inc. reciprocity. DEF 14A. Alnylam Pharmaceuticals, Inc. names Exact Sciences Corp in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Natera, Inc. reciprocity. DEF 14A. Natera, Inc. names Exact Sciences Corp in its own disclosed peer group (read from its most recent proxy). View filing ↗